Pancreatic Cancer Research

ResearcherGarvan Institute of Medical ResearchActive in the last 2 years

Paul Timpson

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-5514-7080; OpenAlex author ID A5064107409. Sources: OpenAlex.

Their work

Papers
32 (first author 0, last author 12)
Trials
0
Grants
0
Labs led
1
Collaborators
79
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: none · 2015: 2 papers · 2016: none · 2017: 3 papers · 2018: 5 papers · 2019: 3 papers · 2020: 4 papers · 2021: 5 papers · 2022: 2 papers · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 4 papers

Papers 32

  1. HSP47 is a potential dual cell target and prognostic factor in pancreatic cancer. Co-author DOI 10.1038/s41388-026-03865-y↗
  2. Cancer cell-intrinsic inflammasome protein ASC links innate immunity with mitochondrial metabolism in driving pancreatic cancer. Co-author DOI 10.1038/s41467-026-69398-w↗
  3. A targetable opioid/cancer associated fibroblast axis drives extracellular matrix remodeling and tumor aggressiveness in pancreatic cancer Co-author DOI 10.64898/2026.05.20.726559↗
  4. Pulsed priming with the FAK inhibitor narmafotinib enhances both gemcitabine/Abraxane and FOLFIRINOX chemotherapy response in pancreatic cancer Last author DOI 10.64898/2026.07.23.740234↗
  5. Targeting the NPY/NPY1R signaling axis in mutant p53-dependent pancreatic cancer impairs metastasis. Co-author DOI 10.1126/sciadv.adq4416↗
  6. Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy response. Last author DOI 10.1126/sciadv.adl1197↗
  7. Focal adhesion kinase priming in pancreatic cancer, altering biomechanics to improve chemotherapy. Co-author DOI 10.1042/bst20220162↗
  8. Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence. Co-author DOI 10.1053/j.gastro.2021.09.022↗
  9. Interfacial Curvature in Confined Coculture Directs Stromal Cell Activity with Spatial Corralling of Pancreatic Cancer Cells. Co-author DOI 10.1002/adbi.202000525↗
  10. Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status. Last author DOI 10.1126/sciadv.abh0363↗
  11. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition. Co-author DOI 10.1158/0008-5472.can-20-2496↗
  12. ROR1 and ROR2 expression in pancreatic cancer. Co-author DOI 10.1186/s12885-021-08952-9↗
  13. Dynamic Stromal Alterations Influence Tumor-Stroma Crosstalk to Promote Pancreatic Cancer and Treatment Resistance. Co-author DOI 10.3390/cancers13143481↗
  14. Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti-tumour immunity through down-regulation of PD-L1. Co-author DOI 10.1016/j.canlet.2019.12.020↗
  15. MCL-1 antagonism enhances the anti-invasive effects of dasatinib in pancreatic adenocarcinoma. Co-author DOI 10.1038/s41388-019-1091-0↗
  16. Targeting genetically-tuned CAFs in pancreatic cancer via perlecan manipulation. Last author DOI 10.1080/14728222.2020.1727887↗
  17. Targeting ROCK activity to disrupt and prime pancreatic cancer for chemotherapy. Last author DOI 10.1080/21541248.2017.1345712↗
  18. CAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer. Last author DOI 10.1016/j.trecan.2019.09.010↗
  19. Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy. Co-author DOI 10.1111/febs.15011↗
  20. Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine. Last author DOI 10.1136/gutjnl-2018-316822↗
  21. Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer. Last author DOI 10.1016/j.celrep.2018.05.038↗
  22. Reshaping the Tumor Stroma for Treatment of Pancreatic Cancer. Last author DOI 10.1053/j.gastro.2017.11.280↗
  23. Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2017-315144↗
  24. Rho Kinase Inhibition by AT13148 Blocks Pancreatic Ductal Adenocarcinoma Invasion and Tumor Growth. Co-author DOI 10.1158/0008-5472.can-17-1339↗
  25. The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/diseases6040103↗
  26. SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer. Co-author DOI 10.1038/onc.2017.63↗
  27. Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Last author DOI 10.1126/scitranslmed.aai8504↗
  28. Transient targeting of the pancreatic cancer stroma as a 'fine-tuned' anti-tumor and anti-metastatic therapy. Last author DOI 10.18632/oncotarget.21468↗
  29. Imaging fibrosis in pancreatic cancer using second harmonic generation. Last author DOI 10.1016/j.pan.2015.02.004↗
  30. Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug effic… Co-author DOI 10.15252/emmm.201404827↗
  31. Intravital FLIM-FRET imaging reveals dasatinib-induced spatial control of src in pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-12-4545↗
  32. Spatial regulation of RhoA activity during pancreatic cancer cell invasion driven by mutant p53. Co-author DOI 10.1158/0008-5472.can-10-2267↗

Closest collaborators

The 25 strongest of 79 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Brooke Pereira · 8 shared papers, 2019–2026 · strength 1.25
  2. Marina Pajic · 13 shared papers, 2015–2021 · strength 1.13
  3. David Herrmann · 9 shared papers, 2017–2026 · strength 1.10
  4. Claire Vennin · 11 shared papers, 2015–2021 · strength 1.00
  5. Jennifer P. Morton · 12 shared papers, 2011–2026 · strength 0.94
  6. Kendelle Joan Murphy · 8 shared papers, 2018–2026 · strength 0.94
  7. Thomas R. Cox · 6 shared papers, 2017–2021 · strength 0.51
  8. Anthony James Gill · 5 shared papers, 2018–2026 · strength 0.51
  9. Amber L. Johns · 5 shared papers, 2018–2026 · strength 0.51
  10. Ashleigh Parkin · 5 shared papers, 2018–2021 · strength 0.44
  11. Phoebe A. Phillips · 3 shared papers, 2021–2026 · strength 0.42
  12. George Sharbeen · 3 shared papers, 2021–2026 · strength 0.42
  13. Angela S. Y. Chou · 5 shared papers, 2018–2021 · strength 0.39
  14. Owen James Sansom · 7 shared papers, 2011–2021 · strength 0.36
  15. Cecilia R. Chambers · 3 shared papers, 2019–2021 · strength 0.35
  16. James R. W. Conway · 4 shared papers, 2017–2021 · strength 0.32
  17. David Goldstein · 2 shared papers, 2021–2026 · strength 0.29
  18. Val Gebski · 2 shared papers, 2021–2026 · strength 0.29
  19. Joshua A. McCarroll · 2 shared papers, 2021–2026 · strength 0.29
  20. Mert Erkan · 2 shared papers, 2021–2026 · strength 0.29
  21. Koroush Shahsavar Haghighi · 2 shared papers, 2021–2026 · strength 0.29
  22. John Kokkinos · 2 shared papers, 2021–2026 · strength 0.29
  23. Minoti Vivek Apte · 2 shared papers, 2021–2026 · strength 0.29
  24. Shona Ritchie · 2 shared papers, 2020–2021 · strength 0.24
  25. Michael F. Olson · 3 shared papers, 2011–2020 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.